ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
06/11/2025
Back to search
Official data from USPTO
UNIQURE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
UNIQURE
ST13
US500000085907857Class
1, 5, 42, 44
Filing
85907857
Registration
4710280
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
46
Latest update
06/12/2025
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
04/18/2013
Registration date
03/31/2015
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/27/2025
Last transaction
06/12/2025
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
26
Owner location
AMSTERDAM, NL
Examiner
LEVINE, HOWARD
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
UNIQURE BIOPHARMA B.V.
uniQure IP B.V.
Representatives
Julianne Abelman ABELMAN LAW PLLC
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Viral assaysviral reagentsviral preparationsgene therapy assaysgene therapy reagentsgene therapy preparationsnucleic acid delivery assaysnucleic acid delivery reagentsnucleic acid delivery preparationsviral vectorsnon-viral vectorsgene therapy vectorsnucleic acid delivery vectorscells transformed by viral vectorsnon-viral vectorsgene therapy vectors and nucleic acid delivery vectorsall for non-medical research purposes
Class 5
Viral medicinesgene therapy medicinesnucleic acid delivery medicinesviral vectorsnon-viral vectorsgene therapy vectorsnucleic acid delivery vectorscells transformed by viral vectorsnon-viral vectorsgene therapy vectors and nucleic acid delivery vectors for medical purposes all for medical treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesfungal diseasesdiseases caused by parasitesdiseases affecting the immune systeminflammatory and auto-immune diseasesvascular disordersbone diseasesinherited disordersgenetic disorderssingle gene disorders and cancers; pharmaceutical preparations and substances for the treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesfungal diseasesdiseases caused by parasitesdiseases affecting the immune systeminflammatory and auto-immune diseasesvascular disordersbone diseasesinherited disordersgenetic disorderssingle gene disorders and cancers; biological preparations for use in medical and clinical gene therapynucleic acid-based therapy and cell therapyall for the treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesfungal diseasesdiseases caused by parasitesdiseases affecting the immune systeminflammatory and auto-immune diseasesvascular disordersbone diseasesinherited disordersgenetic disorderssingle gene disorders and cancers; clinical medical reagents for use in nucleic acid-based therapygene therapycell therapygene diagnosis and gene testing in the treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesfungal diseasesdiseases caused by parasitesdiseases affecting the immune systeminflammatory and auto-immune diseasesvascular disordersbone diseasesinherited disordersgenetic disorderssingle gene disorders and cancers; pharmaceutical preparationsvaccinesprophylaxis medicines and other pharmaceutical preparations all for use in nucleic acid-based therapygene therapy and cell therapy in the treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesfungal diseasesdiseases caused by parasitesdiseases affecting the immune systeminflammatory and auto-immune diseasesvascular disordersbone diseasesinherited disordersgenetic disorderssingle gene disorders and cancers
Class 42
Researchproduct development and consultancy in the field of biotechnologybiologicspharmaceuticsmedical sciencechemistry and biochemistry
Class 44
Gene and nucleic acid deliverygene and nucleic acid transfergene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesinflammatory and auto-immune diseasesvascular disordersinherited disordersgenetic disorders and single gene disorders
Publications
History of USPTO decisions and trademark events.
46 publications found
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
06/04/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/04/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
06/04/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/04/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/04/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
06/04/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
06/04/2025
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
01/27/2025
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
01/27/2025
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
01/27/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/27/2025
E89R
TEAS SECTION 8 & 9 RECEIVED
10/04/2024
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
03/31/2024
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
04/01/2021
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
04/01/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/10/2020
E815
TEAS SECTION 8 & 15 RECEIVED
09/17/2020
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
03/31/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
03/31/2015
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
11/18/2014
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/18/2014
IUCN
NOTICE OF ALLOWANCE CANCELLED
10/29/2014
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
10/29/2014
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
10/28/2014
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/02/2014
PUBO
PUBLISHED FOR OPPOSITION
09/02/2014
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/13/2014
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
07/28/2014
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/28/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/24/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/24/2014
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
07/24/2014
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
02/22/2014
GNFR
FINAL REFUSAL E-MAILED
02/22/2014
CNFR
FINAL REFUSAL WRITTEN
02/22/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/31/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/31/2014
ALIE
ASSIGNED TO LIE
01/26/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/16/2014
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/05/2013
GNRT
NON-FINAL ACTION E-MAILED
08/05/2013
CNRT
NON-FINAL ACTION WRITTEN
08/05/2013
DOCK
ASSIGNED TO EXAMINER
08/05/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/25/2013
NWAP
NEW APPLICATION ENTERED
04/22/2013
Continuous trademark protection
Get notified about every new filing that threatens UNIQURE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.